Show simple item record

dc.contributor.authorHolch, P
dc.contributor.authorHenry, A
dc.contributor.authorDavidson, Susan E
dc.contributor.authorGilbert, A
dc.contributor.authorRoutledge, Jacqueline A
dc.contributor.authorShearsmith, L
dc.contributor.authorFranks, K
dc.contributor.authorIngleson, E
dc.contributor.authorAlbutt, A
dc.contributor.authorVelikova, G
dc.date.accessioned2017-03-04T19:51:37Z
dc.date.available2017-03-04T19:51:37Z
dc.date.issued2017-03-01
dc.identifier.citationAcute and late adverse events associated with radical radiation therapy prostate cancer treatment: a systematic review of clinician and patient toxicity reporting in randomized controlled trials. 2017, 97(3):495-510 Int J Radiat Oncol Biol Physen
dc.identifier.issn1879-355X
dc.identifier.pmid28126299
dc.identifier.doi10.1016/j.ijrobp.2016.11.008
dc.identifier.urihttp://hdl.handle.net/10541/620176
dc.description.abstractThis review aimed to determine the clinician and patient reported outcome (PRO) instruments currently usedin randomized controlled trials (RCTs) of radical radiation therapy for nonmetastatic prostate cancer to report acute and late adverse events (AEs), review the quality of methodology and PRO reporting, and report the prevalence of acute and late AEs.
dc.language.isoenen
dc.rightsArchived with thanks to International journal of radiation oncology, biology, physicsen
dc.titleAcute and late adverse events associated with radical radiation therapy prostate cancer treatment: a systematic review of clinician and patient toxicity reporting in randomized controlled trials.en
dc.typeArticleen
dc.contributor.departmentPsychology Group, School of Social Sciences, Leeds Beckett University, Leedsen
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen
html.description.abstractThis review aimed to determine the clinician and patient reported outcome (PRO) instruments currently usedin randomized controlled trials (RCTs) of radical radiation therapy for nonmetastatic prostate cancer to report acute and late adverse events (AEs), review the quality of methodology and PRO reporting, and report the prevalence of acute and late AEs.


Files in this item

This item appears in the following Collection(s)

Show simple item record